BioSpace News Archive

Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), is partnering, via its wholly owned subsidiary NetraMark Corp. (“NetraMark”), with Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline.

Revenue for the quarter ended December 31, 2021 was $14.6 million compared to $14.3 million for the quarter ended December 31, 2020, an increase of $0.3 million or 2.1%.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022 after the close of the U.S. financial markets.

Vir Biotechnology, Inc. announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.

Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market.

DICE Therapeutics, Inc. announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. ET.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022.

23andMe Holding Co., a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the third quarter of its fiscal year 2022, which ended December 31, 2021.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2021 and reaffirmed its financial guidance for 2022.